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S _ry We searched for mutations of the p53 gene in 25 phaeochromocytomas using polymerase chain
reaction- e strand conformation polymorphism (PCR-SSCP) analysis of the entire conserved regon of
the gene, cxons 4-8; expression of the p53 protein was assessed by immunohistochemistry. No
mutations were found, while a polymorphism in codon 72 was observed. Immunohistochemistry revealed
nudear p53 ovexession in one tumour sample. We conchlde that mutations of the 'hotspot' regon of the
p53 gene do not seem to play a role in the pathogenesis of phaeochromocytoma.
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Although recent studies have identfied the gene involved in
familial forms ofphaeochromocytoma (Viskochil et al., 1990;
Latifet al., 1993; Mulligan et al., 1993), little is known about
the moleular pathogeness of the sporadic variants of the
tumour. It has been shown that a number of phaeoch-
romocytomas have loss ofheterozygosity ofchromosome 17p
(Khosla et al., 1991). The p53 tumour-suppressor gene,
located on this region (17pl3), has been reported as the most
frequent genetic abnormality seen in human malignancies
(Hollstein et al., 1991). This gene codes for a phosphoprotein
that is involved in cell cycle regulation (Lane, 1993; Zambetti
and Levine, 1993). Variations in the gene structure that lead
to impaired function of the p53 protein may confer genetic
instability to the cell, favouring the development ofneoplasia
(Hollstein et al., 1991).
With the aim of detrmining the potential role of p53 in
this tumour, we have searched for mutations in a series of
phaeochromocytomas using polymerase chain reaction-
single strand conformation polymorphism (PCR-SSCP)
analysis of the 'hotspot' region of the gene; the expression of
the p53 protein in tumour samples was also assessed by
immunohistochemistry.
Materak and
Patients
We studied 25 phaeochromocytomas, of which only one was
non-functional. The patients' mean age was 31.4 years (range
9-64 years), with tumour size ranging from 4 to 11.5 cm
(mean 7.2cm). Four tumours were ectra-adrenal. Three of
the tumours were hereditary, originatig from patients with
neurofibromatosis, von Hippel-Lindau disease and familial
phaeochromocytoma (without evidence of the complete mul-
tiple endocrine neoplasia 2A syndrome); the other 22 were
sporadic forms. Twenty-one phaeochromocytomas were
benign and four malignant.
PCR-SSCP analysis
We studied comparatively tumour and constitutive (leuco-
cyte) DNA from all patients. Tumour specimens were
obtained during surgery: a fragment was excised from the
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core of the tumour in order to avoid normal tissue con-
tamination. DNA was extracted by the standard phenol-
chloroform method (Sambrook et al., 1987). PCR of exons
5-8 was performed as previously described (Aguiar et al.,
1995), usng two sets of primers: TGCAGAATTCTG-
ACI1TCACTCTGTCTCCT and GATCAAGCITCCAGA-
GACCCCAGTTGCAAAC for exons 5 and 6; and GAGCT-
CGAGCTCGCGACTGCCTCATCIT and GCATGCGCA-
TGCACCCITGGTCTCCTCCAC for exons 7 and 8. The
amplification protocol of exon 4 consiste in a denaturation
step of 4min at 94C, followed by 35 cycles at 94'C for
1 min, 55C for 1 min and 72-C for 2 min, and a final 7 mi
extension at 72C. The 25yd reactions contained: 400ng of
DNA, 200giM of dNTPs, 1 #iCi of [aC'P]dCrP (6000
Ci mmol' sp. act, Amersham, UK), 2.5 mM magnesium
chloride, 50mM potassium chloride, 10 mM hydrogen chlo-
ride (pH 8.4), 0.5 IU of Taq polymerase (Promega, UK) and
50pmol ofeach ofthe following pru TGCCGTCCCAAG-
CAATGAT and CTGGGAAGGGACAGAAGATGA. The
products of exons 5/6 and 7/8 amplification were digested to
completion with the enzymes StuI and DraI (Gibco/BRL,
Gaithersburg, MD, USA) respectively, according to the
manufacturer's instructions. The restricted fragments corres-
ponding to exons 5, 6, 7 and 8, plus the non-digested exon 4
were diluted in a denaturing solution containing 20mM
EDTA, %% formamide, 0.05% bromophenol blue and
0.05% xylene-cyanoL heat denatured and loaded onto 6%
non-denaturing polyacrylamide gels. The gels were run with-
out or with 10% glycerol. The gels with glycerol were run at
4W overnight and the gels without glycerol at 40W for 2 h,
both at room temperature. The gels were then transferred to
a filter, vacuum dried and autoradiographed at - 70-C. A
normal gene was used as negative control and a chronic
myeloid leukaemia DNA sample harbouring a missense
mutation of exon 7 of the p53 gene was a positive control.
Polymorphism detection ofexon 4
Variations in codon 72 can be recognised by the presence
(arginine) or lack (proline) ofa restiction site for the enzyme
BstUI (New England Biolabs, UK). The PCR products of
exon 4 were digested with this enzyme at 60-C for 18 h, and
the restriction products resolved on a 2% agarose gel.
Immunohistochemistry
A monoclonal antibody directed to both wild-type and
mutant p53, DO-1 (kindly provided by ImmunQtech, Marsei-1212
He, France), recognising the N-terminal portion of the pro-
tein, was used in the formalin-fixed, paraffin-embedded
phaeochromocytoma samples. The immunohistochemical
reaction was performed as previously described (Tsanaclis et
al., 1991), using the peroxidase-antiperoxidase complex
method. The reaction was visualised by aminoethylcarbazole.
A uterine sarcoma sample harbouring a p53 mutation was
used as positive control. The bone marrow cytospin prepara-
tion of a chronic myeloid leukaemia patient harbouring a
p53 mutation (the same used as a positive control of the
SSCP) was a second positive control of the assay. In the
negative control, the primary antibody was replaced by
buffer alone.
DNA sequencing
Exons 4-8 of the sample showing abnormal pattern at
immunohistochemistry were sequenced. Heminested primers,
together with the primers used for the PCR-SSCP analysis,
were used for sequencing exons 5, 6, 7 and 8 (exon 5 ACT-
GAATTCGCCCCAGCTGCTCACCATCG; exon 6 CTG-
GAGAGACGACAGGGCTG: exon 7 ACTGAATTCCAA-
GTGCTCCTGACCTGGA; exon 8 TATAAGCTCCTATC-
CTGAGTAGTGGTAA). The PCR products of the four
exons were gel-purified and directly sequenced with the Cir-
cum Vent thermal cycle DNA sequencing kit (New England
Biolabs. Beverly. MA, USA). according to the manufac-
turer's instructions. The exon 4 fragment was subcloned into
the pCRII vector (Invitrogen, Leek, The Netherlands) and
sequenced using the Sequenase 2.0 kit (US Biochemicals,
Cleveland. OH, USA), according to the manufacturer's
guidelines. Both strands were analysed for confirmation of
the findings.
Results
No specific mutations were found in the DNA from any of
the analysed samples (Figure 1). A polymorphism was found
in exon 4 (codon 72), identified by both SSCP conditions and
restriction analysis with BstUI. Six samples contained a pro-
line (CCC); five, an arginine (CGC). and the remaining 14
were heterozygous. containing both proline and arginine at
this position (Figure 2).
A single sample showed overexpression of p53 protein in
the immunohistochemical analysis. disclosing the expected
nuclear staining pattern in more than 10% of the cells
(Figure 3). Exons 4. 5. 6. 7 and 8 were sequenced and no
mutation was found. This sample contained a proline at
codon 72 and was derived from a sporadic. benign extra-
adrenal phaeochromocytoma.
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F*we 2 Restriction analysis of exon 4 of the p53 gene with
BstUI, as described in Materials and methods. An undigested
control (U). a tumour sample with its germline counterpart con-
taining proline (CCC) in codon 72 (I and IT), a heterozygous
sample containing both arginine (CGC) and proline (2 and 2T)
and a paired sample containing only arginine (3 and 3T) are
shown on a 2% agarose gel stained with ethidium bromide. Note
that the samples containing proline at codon 72 do not have a
recognition site for BstUI. Lane M is 123 bp ladder (Gibco /BRL,
UK).
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Figwe I SSCP analysis of exons 7 and 8 of the p53 gene
digested with DraI. Leucocyte and tumour DNA from phaeoch-
romocytoma patients was examined for the presence of p53
mutations in exons 5-8 by the PCR-SSCP analysis, as described
in Materials and methods. Representative data for exons 7 (top)
and 8 (bottom) from three tumours (t) and their leucocyte
counterparts are shown in lanes 2-6 in a 10% glycerol gel. No
mobility shifts were seen in any tumour compared with the
normal control (lane 9). In contrast, a chronic myeloid leukaemia
sample with a point mutation in exon 7 has a clear elect-
rophoretic mobility shift (lane 8). A double-stranded normal
control is shown in lane 1.
Fugue 3 (a) A p53-immunopositive phaeochromocytoma. Form-
alin-fiaxed, paraffin-embedded phaeochromocytomas were stained
with the p53 antibody DO-1 as described in Materials and
methods. This was the only positive sample in this series. Note
the scattered cells with positive nuclear staining. (b) A negatively
stained phaeochromocytoma sample. Magnification x 10.
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Discussion
We found no mutations of the p53 gene in a representative
population of phaeochromocytomas.
The only abnormal sample in our study at immunohis-
tochemistry was derived from a benign, sporadic, extra-
adrenal phaeochromocytoma. Although an increased poten-
tial for malignant development in extra-adrenal phaeoch-
romocytomas has been suggested (Linnoila et al., 1990), no
metastases were found at surgery in this patient. Addi-
tionally, none of the four malignant phaeochromocytomas
here studied showed molecular or immunohistochemical
abnormalities.
Three other studies have attempted to explore a possible
role for p53 in phaeochromocytomas (Yana et al., 1992;
Yoshimoto et al., 1992; Lin et al., 1994). These studies
produced conflicting results: two of these had results similar
to our own, as no abnormalities in this gene were found
(Yana et al., 1992; Yoshimoto et al., 1992). However, Lin et
al. (1994) found an elevated frequency of p53 mutations,
most of which were located in exon 4, in a small series of
phaeochromocytomas. The analysis of the exon 4 in our
tumours did not show mutations. The polymorphism found
in codon 72 has already been reported (Matlashewski et al.,
1987) and the allelic frequency observed in our samples did
not differ from that previously descnrbed (Weston et al., 1992;
Zhang et al., 1992). Although the proline isoform of p53
protein was found to be twice as stable as the arginine
variant in a cell line (Zhang et al., 1992), and a relative
overrepresentation of the proline isoform in lung adenocar-
cinomas has been described (Weston et al., 1992), an attempt
to associate a potential susceptibility with malignant
phenotype conferred by any of the polymorphic variants has
not been successful (Zhang et al., 1992). Interestingly, our
abnormal sample at immunohistochemistry contained a pro-
line at codon 72. No preferential allele incidence was
observed in our malignant samples.
The finding of immunohistochemical overexpression of p53
protein in a single sample not harbounrng mutation might
result either from structural abnormalities outside the studied
region or from abnormal stabilisation of the wild-type pro-
tein. leading to an increase in its half-life. The former condi-
tion occurs in less than 10% of various human tumours
studied so far (Hollstein et al., 1991). Moreover, mutations
outside the 'hotspot' region are more commonly of the
nonsense type. as opposed to the usual missense mutations
that occur in the 'hotspot' region between exons 5 and 8
(Bodner et al., 1992). These nonsense mutations are expected
to form a truncated mutant protein. unable to react with p53
antibodies, in contrast with the p53 staining observed in our
case. However, factors other than mutations may lead to p53
protein overexpression. These conditions are mostly related
to stabilisation of the protein as a result of binding of p53 to
cellular regulatory proteins, as mdm2 (Momand et al., 1992).
Thus, based on our results, we conclude that mutations of
the 'hotspot' region of p53 gene are unlikely to play an
important role in the origin or development of phaeoch-
romocytoma.
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